NEUROGENE INC (NGNE)
Sector: Health Care
2026 Annual Meeting Analysis
NEUROGENE INC · Meeting: June 3, 2026
Directors FOR
2
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class III Directors
Dr. Baffi has deep biotech industry experience spanning 23 years at BioMarin and 14 years at Genentech; the company's 3-year stock return of +65.4% trails XBI (SPDR S&P Biotech ETF) by only 1.0 percentage point, well below the 65-point threshold required to trigger an against vote, so no TSR concern applies; no overboarding, attendance, or independence issues were identified.
Mr. Palekar brings extensive biopharmaceutical executive leadership experience including serving as CEO of 89bio until its acquisition by Roche; the company's 3-year stock return of +65.4% trails XBI (SPDR S&P Biotech ETF) by only 1.0 percentage point, well below the 65-point threshold required to trigger an against vote; no overboarding, attendance, or independence issues were identified.
Both Class III director nominees have relevant biotech industry experience and no material governance concerns. The company's 3-year total shareholder return of +65.4% is essentially in line with the XBI (SPDR S&P Biotech ETF) at +66.4%, falling only 1.0 percentage point short — far below the 65-point underperformance threshold needed to trigger a withhold vote under the strong-positive-TSR tier. Both nominees receive a FOR vote.
Say on Pay
✓ FORCEO
Rachel McMinn
Total Comp
$3,209,553
Prior Support
N/A
CEO Rachel McMinn received total compensation of $3,209,553 in 2025, which is reasonable for a biotech CEO at a company of Neurogene's stage and market cap. Pay mix is appropriate: base salary of $618,800 represents roughly 19% of total compensation, with the remainder in variable stock awards, stock options, and a performance-based annual bonus — well exceeding the 50-60% variable pay threshold. The company's stock returned +125.6% over the past year and +65.4% over three years, roughly in line with the XBI (SPDR S&P Biotech ETF), supporting the conclusion that incentive pay is aligned with shareholder experience. Performance-based awards including performance stock units tied to clinical development milestones were incorporated, demonstrating meaningful performance conditions.
Auditor Ratification
✓ FORAuditor
Deloitte & Touche LLP
Tenure
3 yrs
Audit Fees
$792,752
Non-Audit Fees
$0
Deloitte has served as auditor since 2023 (approximately 3 years), well below the 25-year tenure threshold that would raise independence concerns. All fees paid in 2025 were audit fees ($792,752) with zero non-audit, audit-related, or tax fees, meaning the non-audit fee ratio is 0% — far below the 50% threshold that would trigger a concern. Deloitte is a Big 4 firm appropriate for a company of Neurogene's size and complexity.
Overall Assessment
Neurogene's 2026 annual meeting ballot is straightforward with no significant governance concerns. The director nominees are qualified biotech veterans, the company's stock performance is broadly in line with the XBI (SPDR S&P Biotech ETF) benchmark, executive pay is structured with meaningful variable and performance-linked components at reasonable absolute levels, and the auditor fees show a clean 0% non-audit ratio with a short 3-year tenure.